Endocrine Gland Disorders – Drugs In Development, 2023
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Global Markets Direct’s, ‘Endocrine Gland Disorders – Drugs In Development, 2023’, provides an overview of the Endocrine Gland Disorders pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Endocrine Gland Disorders, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Endocrine Gland Disorders and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
- The report provides a snapshot of the global therapeutic landscape of Endocrine Gland Disorders
- The report reviews pipeline therapeutics for Endocrine Gland Disorders by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Endocrine Gland Disorders therapeutics and enlists all their major and minor projects
- The report assesses Endocrine Gland Disorders therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Endocrine Gland Disorders
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Endocrine Gland Disorders
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Endocrine Gland Disorders pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Players
Addpharma IncAmphastar Pharmaceuticals Inc
Aprilbio Co Ltd
Arbor Pharmaceuticals LLC
Atropos Therapeutics Inc
Azurity Pharmaceuticals Inc
CaraVan Biologix Inc
Citrine (Shanghai) Co Ltd
Consegna Pharma Inc
Daewon Pharmaceutical Co Ltd
Eiger BioPharmaceuticals Inc
Eton Pharmaceuticals Inc
Generium
Genflow Biosciences Srl
Gubra ApS
HLK Pharmacin LLC
Hyloris Pharmaceuticals SA
Korea United Pharm Inc
Lumos Pharma Inc
LyGenesis Inc
MBX Biosciences Inc
Neurocrine Biosciences Inc
Novartis AG
OMass Therapeutics Limited
PRG S&Tech Inc
ProGeLife SAS
Promomed Rus
Salk Institute for Biological Studies
Scohia Pharma Inc
Shandong Xinhua Pharmaceutical Co Ltd
Ziphius Vaccines NV